Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

BACKGROUND: Inclisiran, an siRNA administered twice-yearly, significantly reduced LDL cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into a lower risk of cardiovascular (CV) events is not yet established. METHODS AND RESULTS: Patient-level, pooled analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Kausik K, Raal, Frederick J, Kallend, David G, Jaros, Mark J, Koenig, Wolfgang, Leiter, Lawrence A, Landmesser, Ulf, Schwartz, Gregory G, Lawrence, David, Friedman, Andrew, Garcia Conde, Lorena, Wright, R Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825807/
https://www.ncbi.nlm.nih.gov/pubmed/36331326
http://dx.doi.org/10.1093/eurheartj/ehac594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825807/
https://www.ncbi.nlm.nih.gov/pubmed/36331326
http://dx.doi.org/10.1093/eurheartj/ehac594

Ejemplares similares